Goldenwell Biotech, Inc. (GWLL) Stock
Goldenwell Biotech, Inc., focuses on nutraceutical and dietary supplements business in the United States. It is developing JI MAI, a bovine cardiac vascular active peptide; Double Proline AG, a 3D active collagen peptide drinkable cosmetic; Cartilage Peptide, a Type II collagen peptide; and Sugar Master, a dietary supplement.
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Cash Flow (USD)
Valuation & Return Ratios
Peer Comparison
About Goldenwell Biotech, Inc.
Goldenwell Biotech, Inc., focuses on nutraceutical and dietary supplements business in the United States. It is developing JI MAI, a bovine cardiac vascular active peptide; Double Proline AG, a 3D active collagen peptide drinkable cosmetic; Cartilage Peptide, a Type II collagen peptide; and Sugar Master, a dietary supplement. The company was incorporated in 2019 and is based in Hudson, Ohio.
Goldenwell Biotech, Inc. is headquartered in US.
Goldenwell Biotech, Inc. (GWLL) stock trades at $0.90 with a market capitalization of $89.10M. The stock is valued at a price-to-earnings (P/E) ratio of -346.15, price-to-book of -259.23, price-to-sales of 1468.00. Over the past 52 weeks the stock has ranged between $0.20 and $10.00, and currently trades 91.0% below its 52-week high.
On profitability, Goldenwell Biotech, Inc. generates a return on equity (ROE) of 100.43% — well above the market average, a sign of a high-quality business, return on capital employed of 77.83%, an operating margin of -104.18%, a net profit margin of -379.85%.
Official website: www.goldenwellbiotech.com